Adapted from Duval & Soussy (1980) . At usual dosages, these drugs are bacteriostatic but synergic effects have been reported when used in combination with rifampicin and aminoglycosides. Pristinamycin was found to be bactericidal against 69 % of 16 coagulase-positive or -negative staphylococcal strains responsible for septicaemia when combined with rifampicin and against 50% of these strains when combined with aminoglycosides (Table II) . Adapted from Bastin et al. (1977) .
Pharmacokinetics
Except for erythromycin for which a parenteral form is available (as the lactobionate salt), macrolides and streptogramins can be administered only by the oral route, which limits their use in severe infections. Lincosamides can be administered by the oral or by the parenteral route.
MLS are well distributed in most tissues, except for cerebro spinal fluid and brain. Spiramycin differs from the other related drugs in its far higher tissue concentrations and also by its high concentrations in secretions, notably saliva and milk. Lincosamides, and especially clindamycin, are characterized by their marked concentration in bone tissue, particularly when infected. As for streptogramins, they concentrate in skin and bones.
All MLS are excreted mainly through the liver and bile and only to a minor degree in urine. In fact, no preference can be given to any particular antibiotic of this group on purely pharmacokinetic grounds in the treatment of staphylococcal infections.
Tolerance
True macrolides are among the best tolerated antibiotics and the symptoms they are likely to cause are minor and uncommon. They include gastrointestinal disorders, allergic reactions, and cholestatic hepatitis (with oleandomycin or erythromycin estolate). Transient deafness has also been observed with very high doses of erythromycin.
Among the side-effects of lincosamides, which are in many respects quite similar to those induced by true macrolides, diarrhoea is the most prominent; it is observed in almost 20% of patients, mainly after oral administration. In 10% of cases, this disorder is associated with pseudomembraneous colitis which may be fatal in some cases. In spite of the well-established effectiveness of lincosamides in staphylococcal infections, the high incidence and seriousness of their side-effects restrict their use to infections, mainly those due to Bacteroides spp., where they appear to be clearly superior to other better tolerated drugs.
Even when treatment is prolonged over several months, streptogramins are better (or at least as well) tolerated than true macrolides and should therefore in this respect be definitively preferred to lincosamides.
Indications in staphylococcal infections
The choice of the antibiotic treatment in staphylococcal infections is based on the sensitivity of the isolated strain. Until sensitivity testing has been performed, the infecting strain must be considered as likely to produce a penicillinase. First-line treatment should therefore include either a penicillinase-resistant penicillin or a macrolide (or any related compound), possibly in combination with an aminoglycoside in severe infections. True macrolides are less active but better tolerated than lincosamides. Lincosamides are as effective as streptogramins but the percentage of strains resistant to lincosamides is substantially higher and their side-effects are more frequent and more severe. Indeed, due to their uniform activity and to their excellent tolerance, streptogramins appear to be the best antistaphylococcal agents among the MLS group, although they cannot be administered by the parenteral route and the serum bactericidal activity cannot be determined (Table III) . The main indications of streptogramins in infectious diseases due to staphylococci include:
(1) Skin infections, and more particularly pyoderma, boils, impetigo, superinfected dermatosis, post-chickenpox cellulitis and lymphangitis. Streptogramins have also the advantage of being active against streptococci, which play an important part in skin infections where bacteriological diagnosis is rarely possible. In contrast, streptogramins are contraindicated in chronic suppurative processes, and infected varicose and trophic ulcers owing to the multi-bacterial nature of these lesions and to the resistance of the isolated causative pathogens.
(2) Osteoarticular infections where, owing to their excellent tolerance, they are usually given as second-line therapy, often for prolonged periods, after an initial treatment combining a penicillinase-resistant penicillin and an aminoglycoside. Some clinicians, however, initiate treatment right away with a streptogramin in combination with an aminoglycoside or nfampicin.
(3) Bacteraemia: the administration of a streptogramin in combination with an aminoglycoside, vancomycin or rifampicin may be considered but their bacterial synergic effect appears to be inconsistent and the lack of a parenteral form does limit their use.
